肿瘤细胞治疗研究
英文原题：Seeing Is Believing: IEC-HS after CAR T Cells.
Seeing Is Believing: IEC-HS after CAR T Cells.
免疫效应细胞相关噬血细胞性淋巴组织细胞增生症样综合征（IEC-HS）是接受嵌合抗原受体（CAR）T 细胞患者中出现的并发症，与 CD19 相比，在 CD22 或 BCMA 靶向构建体患者中更为常见。
免疫效应细胞相关噬血细胞性淋巴组织细胞增多症样综合征（IEC-HS）是嵌合抗原受体（CAR）T细胞治疗的一种并发症；与靶向CD19的构建体相比，接受靶向CD22或BCMA构建体治疗的患者中更常见。IEC-HS与CAR-T细胞扩增增加及独特的细胞因子谱相关，其中IFNγ、IL-10和IL-1受体拮抗剂（IL-1RA）三种细胞因子的组合与IEC-HS严重程度相关性最强，可能有助于指导预先干预。相关研究见Srinagesh等人发表的文章，第225页。
Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) is a complication seen in patients receiving chimeric antigen receptor (CAR) T cells, more frequently in those with CD22- or BCMA-targeted constructs compared with CD19. While associated with higher CAR T-cell expansion and a unique cytokine profile, the constellation of three cytokines (IFN , IL10, and IL1RA) correlated most strongly with IEC-HS severity and may help guide preemptive interventions. See related article by Srinagesh et al., p. 225.
MEMBER ACCOUNT
登录成功会直接打开下一页。
